Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-009404
Filing Date
2023-05-11
Accepted
2023-05-11 16:23:36
Documents
61
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q rvlp-20230331x10q.htm   iXBRL 10-Q 976484
2 EX-31.1 rvlp-20230331xex31d1.htm EX-31.1 11169
3 EX-32.1 rvlp-20230331xex32d1.htm EX-32.1 8015
  Complete submission text file 0001558370-23-009404.txt   4562898

Data Files

Seq Description Document Type Size
4 EX-101.SCH rvlp-20230331.xsd EX-101.SCH 42067
5 EX-101.CAL rvlp-20230331_cal.xml EX-101.CAL 49397
6 EX-101.DEF rvlp-20230331_def.xml EX-101.DEF 142119
7 EX-101.LAB rvlp-20230331_lab.xml EX-101.LAB 346085
8 EX-101.PRE rvlp-20230331_pre.xml EX-101.PRE 244582
55 EXTRACTED XBRL INSTANCE DOCUMENT rvlp-20230331x10q_htm.xml XML 655082
Mailing Address 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807
Business Address 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807 9088091300
RVL Pharmaceuticals plc (Filer) CIK: 0001739426 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38709 | Film No.: 23911413
SIC: 2834 Pharmaceutical Preparations